Cresset Asset Management LLC Has $647,000 Holdings in CVRx, Inc. (NASDAQ:CVRX)

Cresset Asset Management LLC boosted its holdings in CVRx, Inc. (NASDAQ:CVRX) by 20.5% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 51,102 shares of the company’s stock after acquiring an additional 8,699 shares during the quarter. Cresset Asset Management LLC’s holdings in CVRx were worth $647,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Tower Research Capital LLC TRC boosted its stake in CVRx by 43.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,900 shares of the company’s stock valued at $49,000 after buying an additional 1,186 shares in the last quarter. Quarry LP acquired a new position in shares of CVRx in the fourth quarter valued at approximately $69,000. MetLife Investment Management LLC acquired a new position in shares of CVRx in the fourth quarter valued at approximately $111,000. Wells Fargo & Company MN increased its stake in shares of CVRx by 86.1% in the fourth quarter. Wells Fargo & Company MN now owns 8,894 shares of the company’s stock valued at $113,000 after buying an additional 4,115 shares during the period. Finally, Boothbay Fund Management LLC acquired a new position in shares of CVRx in the fourth quarter valued at approximately $127,000. 75.27% of the stock is owned by institutional investors and hedge funds.

CVRx Stock Up 14.5%

CVRx stock opened at $5.44 on Wednesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 10.23 and a current ratio of 12.06. CVRx, Inc. has a 52-week low of $4.30 and a 52-week high of $18.55. The firm has a 50 day moving average price of $9.01 and a two-hundred day moving average price of $12.53. The firm has a market cap of $141.75 million, a price-to-earnings ratio of -2.02 and a beta of 1.39.

CVRx (NASDAQ:CVRX) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.03. CVRx had a negative net margin of 116.91% and a negative return on equity of 93.06%. The firm had revenue of $12.35 million during the quarter, compared to analyst estimates of $14.68 million. Equities analysts predict that CVRx, Inc. will post -1.91 EPS for the current year.

Analyst Upgrades and Downgrades

CVRX has been the subject of several recent research reports. JPMorgan Chase & Co. reaffirmed an “underweight” rating and issued a $7.00 price objective (down previously from $15.00) on shares of CVRx in a research note on Friday, May 9th. Craig Hallum upped their price objective on CVRx from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Friday, January 17th. Piper Sandler lowered their price objective on CVRx from $20.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday, May 9th. Lake Street Capital lowered their price objective on CVRx from $19.00 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, April 8th. Finally, Canaccord Genuity Group lowered their price objective on CVRx from $23.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $14.50.

CVRx Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.